Phase II Trial of Lenalidomide - Rituximab ± Dexamethasone in Relapsed or Refractory Indolent B-Cell or Mantle Cell Lymphomas Resistant to Rituximab

被引：0
作者：
Ahmadi, Tahamtan
Chong, Elise A. [1 ]
Gordon, Amanda [1 ]
Aqui, Nicole A. [2 ]
Xu, YinYan [2 ]
Svoboda, Jakub [1 ]
Nasta, Sunita D. [1 ]
Schuster, Stephen J. [1 ]
机构：
[1] Univ Penn, Abramson Canc Ctr, Lymphoma Program, Philadelphia, PA 19104 USA
[2] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：122 / 123
页数：2
相关论文
共 50 条
  • [31] Rituximab, gemcitabine, cisplatin, and dexamethasone in patients with refractory or relapsed aggressive B-cell lymphoma
    Hou, Yun
    Wang, Hua-qing
    Ba, Yi
    MEDICAL ONCOLOGY, 2012, 29 (04) : 2409 - 2416
  • [32] Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma
    Robinson, K. Sue
    Williams, Michael E.
    van der Jagt, Richard H.
    Cohen, Philip
    Herst, Jordan A.
    Tulpule, Anil
    Schwartzberg, Lee S.
    Lemieux, Bernard
    Cheson, Bruce D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (27) : 4473 - 4479
  • [33] Bendamustine and rituximab act synergistically in vitro and are effective in the treatment of relapsed or refractory indolent and mantle-cell lymphomas.
    Rummel, MJ
    Kim, SZ
    Chow, KU
    Welslau, M
    Al-Batran, S
    Kofahl-Krause, D
    Rost, A
    Josten, KM
    Hecker, R
    von Gruenhagen, U
    Neise, M
    Hoelzer, D
    Mitrou, PS
    BLOOD, 2003, 102 (11) : 104A - 104A
  • [34] Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial
    Changhee Park
    Ho Sup Lee
    Ka-Won Kang
    Won-Sik Lee
    Young Rok Do
    Jae-Yong Kwak
    Ho-Jin Shin
    Sung-Yong Kim
    Jun Ho Yi
    Sung-Nam Lim
    Jeong-Ok Lee
    Deok-Hwan Yang
    Hun Jang
    Byoungsan Choi
    Jiwoo Lim
    Choong Hyun Sun
    Ja Min Byun
    Sung-Soo Yoon
    Youngil Koh
    Nature Communications, 15
  • [35] Re-treatment of relapsed indolent B-cell lymphoma with rituximab
    Igarashi, T
    Ohtsu, T
    Fujii, H
    Sasaki, Y
    Morishima, Y
    Ogura, M
    Kagami, Y
    Kinoshita, T
    Kasai, M
    Kiyama, Y
    Kobayashi, Y
    Tobinai, K
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2001, 73 (02) : 213 - 221
  • [36] Re-Treatment of Relapsed Indolent B-Cell Lymphoma With Rituximab
    Tadahiko Igarashi
    Tomoko Ohtsu
    Hirofumi Fujii
    Yasutsuna Sasaki
    Yasuo Morishima
    Michinori Ogura
    Yoshitoyo Kagami
    Tomohiro Kinoshita
    Masaharu Kasai
    Yoshio Kiyama
    Yukio Kobayashi
    Kensei Tobinai
    International Journal of Hematology, 2001, 73 : 213 - 221
  • [37] Systemic rituximab in the treatment of indolent primary cutaneous B-cell lymphomas
    Muniesa, C.
    Domingo, E.
    Fornons, R.
    Penate, Y.
    Estrach, T.
    Ramon, D.
    Medina, S.
    Florez, A.
    Ortiz, P.
    Sanchez, P.
    Torres, I.
    Acebo, E.
    Yanguas, I.
    Fernandez de Misa, R.
    Blanes, M.
    Zayas, A.
    Descalzo, M. A.
    Garcia-Doval, I.
    Servitje, O.
    EUROPEAN JOURNAL OF CANCER, 2019, 119 : S36 - S36
  • [38] Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial
    Park, Changhee
    Lee, Ho Sup
    Kang, Ka-Won
    Lee, Won-Sik
    Do, Young Rok
    Kwak, Jae-Yong
    Shin, Ho-Jin
    Kim, Sung-Yong
    Yi, Jun Ho
    Lim, Sung-Nam
    Lee, Jeong-Ok
    Yang, Deok-Hwan
    Jang, Hun
    Choi, Byoungsan
    Lim, Jiwoo
    Sun, Choong Hyun
    Byun, Ja Min
    Yoon, Sung-Soo
    Koh, Youngil
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [39] Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study
    Jermann, M
    Jost, LM
    Taverna, C
    Jacky, E
    Honegger, HP
    Betticher, DC
    Egli, F
    Kroner, T
    Stahel, RA
    ANNALS OF ONCOLOGY, 2004, 15 (03) : 511 - 516
  • [40] Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma
    Dang, Nam H.
    Fayad, Luis
    McLaughlin, Peter
    Romaguara, Jorge E.
    Hagemeister, Fredrick
    Goy, Andre
    Neelapu, Sattva
    Samaniego, Felipe
    Walker, Pamela L.
    Wang, Michael
    Rodriguez, Maria A.
    Tong, Ann T.
    Pro, Barbara
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 138 (04) : 502 - 505
12345